Journal Club Presentation by Dr. Neal Shah

Created using ChatSlide

This lecture provides a comprehensive overview of a pivotal study on semaglutide, recently published in NEJM, examining its effects on individuals with Type 2 diabetes and chronic kidney disease (CKD). Emphasizing significant outcomes from the FLOW trial, it showcases semaglutide’s potential in reducing kidney disease risk by 24% and cardiovascular events by 18%. The session will analyze the study's design, key findings, and implications for clinical practice while addressing health...